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Abstract
Soybean MON 87708 9 MON 89788 9 A5547-127 (three-event stack soybean) was produced by
conventional crossing to combine three single events: MON 87708, MON 89788 and A5547-127. The
GMO Panel previously assessed the three single events and did not identify safety concerns. No new
data on the single events, leading to modification of the original conclusions on their safety have been
identified. The molecular characterisation, comparative analysis (agronomic, phenotypic and
compositional characteristics) and the outcome of the toxicological, allergenicity and nutritional
assessment indicate that the combination of the single soybean events and of the newly expressed
proteins in the three-event stack soybean does not give rise to food and feed safety and nutritional
concerns. The GMO Panel concludes that the three-event stack soybean, as described in this
application, is as safe as and nutritionally equivalent to its conventional counterpart and the non-GM
reference varieties tested. The nutritional impact of food/feed derived from the three-event stack
soybean is expected to be the same as that of food/feed derived from the conventional counterpart
and non-GM reference varieties. In the case of accidental release of viable seeds of the three-event
stack soybean into the environment, this would not raise environmental safety concerns. The post-
market environmental monitoring plan and reporting intervals are in line with the intended uses of the
three-event stack soybean. Post-market monitoring of food/feed is not considered necessary. The GMO
Panel concludes that the three-event stack soybean is as safe as its conventional counterpart and the
tested non-GM reference varieties with respect to potential effects on human and animal health and
the environment.
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Summary
Following the submission of application EFSA-GMO-NL-2016-135 under Regulation (EC) No 1829/2003
from Monsanto (hereafter referred to as ‘the applicant’), the Panel on Genetically Modified Organisms of the
European Food Safety Authority (hereafter referred to as the ‘GMO Panel’) was asked to deliver a scientific
opinion on genetically modified (GM) soybean MON 87708 9 MON 89788 9 A5547-127 (hereafter
referred to as ‘the three-event stack soybean’). The scope of application EFSA-GMO-NL-2016-135 is for the
placing on the market of the three-event stack soybean for food and feed uses, import and processing.
The three-event stack soybean was produced by conventional crossing to combine three single
soybean events: MON 87708 (producing DMO), MON 89788 (producing CP4 EPSPS) and A5547-127
(producing PAT), to confer tolerance to dicamba, glyphosate and glufosinate-ammonium containing
herbicides.
The GMO Panel evaluated the three-event stack soybean with reference to the scope and
appropriate principles described in its guidelines for the risk assessment of GM plants and derived food
and feed, the environmental risk assessment of GM plants and the post-market environmental
monitoring (PMEM) of GM plants. The GMO Panel considered the information available on the single
events, the three-event stack soybean, the scientific comments submitted by the Member States and
the relevant scientific literature.
The single events MON 87708, MON 89788 and A5547-127 were previously assessed by the
European Food Safety Authority (EFSA) and no concerns on their safety were identified. No new safety
issue was identified by updated bioinformatic analyses, nor reported by the applicant concerning the
three single soybean events, since the publication of the respective scientific opinions. Consequently,
the GMO Panel considers that its previous conclusions on the safety of the single soybean events
remain valid.
For the three-event stack soybean, the risk assessment included the molecular characterisation of
the inserted DNA and analysis of protein expression. An evaluation of the comparative analysis of
agronomic/phenotypic and compositional characteristics was undertaken, and the safety of the newly
expressed proteins and the whole food and feed were evaluated with respect to potential toxicity,
allergenicity and nutritional characteristics. An evaluation of environmental impacts and the PMEM plan
was also undertaken.
The molecular characterisation data establish that the events stacked in the three-event stack
soybean have retained their integrity. Protein expression analyses show that the levels of the newly
expressed proteins are comparable in the three-event stack and in the single events. No indications of
interactions that may affect the integrity of the events and the levels of the newly expressed proteins
in this three-event stack soybean are identified.
The comparative analysis of forage and seed composition and agronomic/phenotypic characteristics
identified no differences between the three-event stack soybean and its conventional counterpart that
required further assessment for food/feed safety or environmental impact, except for the levels of acid
detergent fibre, total fat and behenic acid in seeds. All those changes were further assessed and not
found to have a safety impact.
The molecular characterisation, the comparative analysis and the outcome of the toxicological,
allergenicity and nutritional assessment indicate that the combination of the single soybean events and
of the newly expressed proteins in the three-event stack soybean does not give rise to food and feed
safety and nutritional concerns. The GMO Panel concludes that soybean MON 87708 9 MON
89788 9 A5547-127, as described in this application, is as safe as and nutritionally equivalent to its
conventional counterpart and the commercial non-GM soybean reference varieties (hereafter ‘non-GM
reference varieties’) tested.
Considering the combined events and their potential interactions, the outcome of the comparative
analysis, and the routes and levels of exposure, the GMO Panel concludes that soybean
MON 87708 9 MON 89788 9 A5547-127 would not raise safety concerns in the case of accidental
release of viable GM soybean seeds into the environment.
Given the absence of safety concerns for foods and feeds from the three-event stack soybean, the
GMO Panel considers that post-market monitoring of food/feed is not considered necessary. The PMEM
plan and reporting intervals are in line with the intended uses of the three-event stack soybean. The
literature searches did not identify any relevant publications on the three-event stack soybean. In the
context of annual PMEM reports, the applicant should improve future literature searches according to
the GMO Panel recommendations.
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The GMO Panel concludes that soybean MON 87708 9 MON 89788 9 A5547-127, as described in
this application, is as safe as its conventional counterpart and the tested non-GM reference varieties
with respect to potential effects on human and animal health and the environment.
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1. Introduction
The scope of application EFSA-GMO-NL-2016-135 is for food and feed uses, import and processing
in the European Union (EU) of the genetically modified (GM) herbicide tolerant soybean MON
87708 9 MON 89788 9 A5547-127.
1.1. Background
On 3 November 2016, the European Food Safety Authority (EFSA) received from the Competent
Authority of the Netherlands the application EFSA-GMO-NL-2016-135 for authorisation of soybean MON
87708 9 MON 89788 9 A5547-127 (Unique Identifiers MON-877Ø8-9 9 MON-89788-1 9 ACS-
GMØØ6-4), submitted by Monsanto (hereafter referred to as ‘the applicant’) according to Regulation
(EC) No 1829/2003.1
Following receipt of application EFSA-GMO-NL-2016-135, EFSA informed the EU Member States
(MS) and the European Commission, and made the summary of the application available to the public
on the EFSA website.2
EFSA checked the application for compliance with the relevant requirements of Regulation (EC)
No 1829/2003 and Regulation (EU) No 503/2013,3 and, when needed, asked the applicant to
supplement the initial application. On 19 January 2017, EFSA declared the application valid, and made
the valid application available to the EU MS and EC.
From the validity date, EFSA and its scientific Panel on Genetically Modified Organisms (hereafter
referred to as the ‘GMO Panel’) endeavoured to respect a time limit of 6 months to issue a scientific
opinion on application EFSA-GMO-NL-2016-135. Such time limit was extended whenever EFSA and/or
its GMO Panel requested supplementary information to the applicant. According to Regulation (EC)
No 1829/2003, any supplementary information provided by the applicant during the risk assessment
was made available to the EU MS and European Commission (for further details, see the
Section ‘Documentation’, below).
In accordance with Regulation (EC) No 1829/2003, EFSA consulted the nominated risk assessment
bodies of EU MS, including national Competent Authorities within the meaning of Directive 2001/18/EC.4
The EU MS had 3 months to make their opinion known on the application EFSA-GMO-NL-2016-135 as of
date of validity.
1.2. Terms of Reference as provided by the requestor
According to Articles 6 and 18 of Regulation (EC) No 1829/2003, EFSA and its GMO Panel were
requested to carry out a scientific risk assessment of soybean MON 87708 9 MON 89788 9 A5547-127
in the context of its scope as defined in application EFSA-GMO-NL-2016-135.
According to Regulation (EC) No 1829/2003, this scientific opinion is to be seen as the report
requested under Articles 6(6) and 18(6) of that Regulation including the opinions of the nominated risk
assessment bodies of EU MS.5
In addition to the present scientific opinion on soybean MON 87708 9 MON 89788 9 A5547-127,
EFSA and its GMO Panel were also asked to report on the particulars listed under Articles 6(5) and 18
(5) of Regulation (EC) No 1829/2003. The information required under Annex II to the Cartagena
Protocol, a labelling proposal as well as a Post-Market Environmental Monitoring (PMEM) plan as
provided by the applicant are made available in the EFSA Register of Questions.6 Whereas the method
(s), validated by the Community Reference Laboratory, for detection, including sampling, identification
of the transformation event in the food-feed and/or foods-feeds produced from it can be found at
http://gmo-crl.jrc.ec.europa.eu/StatusOfDossiers.aspx, [Validation report MON 87708 9 MON 89788 9
1 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modified
food and feed. OJ L 268, 18.10.2003, p. 1–23.
2 Available online at the EFSA Register of Questions (http://registerofquestions.efsa.europa.eu/roqFrontend/questionDocume
ntsLoader?question=EFSA-Q-2016-00688).
3 Commission Implementing Regulation (EU) No 503/2013 of 3 April 2013 on applications for authorisation of genetically
modified food and feed in accordance with Regulation (EC) No 1829/2003 of the European Parliament and of the Council and
amending Commission Regulations (EC) No 641/2004 and (EC) No 1981/2006. OJ L157, 8.6.2013, p. 1–48.
4 Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the
environment of genetically modified organisms and repealing Council Directive 90/220/EEC. OJ L 106, 12.3.2001, p. 1–38.
5 Opinions of the nominated risk assessment bodies of EU MS can be found at the EFSA Register of Questions (http://registerof
questions.efsa.europa.eu/roqFrontend/questionDocumentsLoader?question=EFSA-Q-2016-00688).
6 http://registerofquestions.efsa.europa.eu/roqFrontend/questionDocumentsLoader?question=EFSA-Q-2016-00688
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A5547-127; Validated methods: MON 87708, MON 89788, A5547-127; DNA extraction]. The appropriate
reference materials can be accessed at https://www.aocs.org/ (MON 87708, MON 89788, A5547-127).
2. Data and methodologies
2.1. Data
The GMO Panel based its scientific risk assessment of soybean MON 87708 9 MON
89788 9 A5547-127 on the valid application EFSA-GMO-NL-2016-135, additional information provided
by the applicant during the risk assessment, relevant scientific comments submitted by EU MS and
relevant peer-reviewed scientific publications. In addition to this comprehensive information package,
the GMO Panel also received unpublished studies submitted by the applicant in order to comply with
the specific provisions of Regulation (EU) No 503/2013. A list of these additional unpublished studies is
provided in Appendix B.
2.2. Methodologies
The GMO Panel conducted its assessment in line with the principles described in Regulation (EU)
No 503/2013, its applicable guidelines (i.e., EFSA GMO Panel, 2010a,b, 2011a,b, 2015a) and
explanatory notes (i.e., EFSA, 2014, 2017a,b) for the risk assessment of GM plants. During its risk
assessment, the GMO Panel considered all additional unpublished studies as listed in Appendix B for
potential effects on human and animal health and the environment.
For the assessment of 90-day animal feeding studies, the GMO Panel took into account the criteria
included in the 2011 EFSA Scientific Committee guidance on conducting repeated-dose 90-day oral
toxicity study in rodents on whole food/feed and the explanatory statement for its applicability (EFSA,
2014).
The GMO Panel also assessed the applicant’s literature searches, which include a scoping review, in
accordance with the recommendations on literature searching outlined in EFSA (2010, 2017a).
In the frame of the contracts OC/EFSA/GMO/2013/01 and OC/EFSA/GMO/2014/01, contractors
performed preparatory work and delivered reports on the methods applied by the applicant in
performing bioinformatic and statistical analyses, respectively.
3. Assessment
3.1. Introduction
Application EFSA-GMO-NL-2016-135 covers soybean MON 87708 9 MON 89788 9 A5547-127. This
three-event stack was produced by conventional crossing to combine three single soybean events:
MON 87708 (expressing dicamba mono-oxygenase (DMO protein)), MON 89788 (expressing the
5-enolpyruvylshikimate-3-phosphate synthase (CP4 EPSPS protein)) and A5547-127 (expressing
phosphinothricin acetyltransferase (PAT protein)), to confer tolerance to dicamba, glyphosate and
glufosinate-ammonium-containing herbicides. It should be noted that the assessment of herbicide
residues relevant for this application has been investigated by the EFSA Pesticides Unit (EFSA, 2013,
2015a, 2018).
The three single events were assessed previously (see Table 1) and no concerns for human and
animal health or environmental safety were identified.
Table 1: Single soybean events already assessed by the GMO Panel
Events Application or mandate Reference
MON 87708 EFSA-GMO-NL-2011-93 EFSA GMO Panel (2013)
MON 89788 EFSA-GMO-NL-2006-36 EFSA (2008)
A5547-127 EFSA-GMO-NL-2008-52 EFSA GMO Panel (2011c)
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3.2. Updated information on single events7,8
Since the publication of the scientific opinions on the single soybean events (see Table 1), no safety
issue concerning the three single events has been reported by the applicant.
Updated bioinformatic analyses for soybean events MON 87708, MON 89788 and A5547-127
confirm that no known endogenous genes were disrupted by any of the inserts.
Updated bioinformatic analyses of the amino acid sequence of the newly expressed DMO, CP4
EPSPS and PAT proteins confirm previous results indicating no significant similarities to toxins and
allergens. Updated bioinformatic analyses of the newly created open reading frames (ORFs) within the
inserts, or spanning the junctions between the insert and the flanking regions for soybean events MON
87708, MON 89788 and A5547-127, confirm previous analyses, indicating that the expression of an
ORF showing significant similarities to toxins or allergens is highly unlikely (see Table 1).
In order to assess the possibility for horizontal gene transfer (HGT) by homologous recombination
(HR), the applicant performed a sequence identity analysis for soybean events MON 87708, MON
89788 and A5547-127 to microbial DNA. The likelihood and potential consequences of plant-to-bacteria
gene transfer are described in Section 3.7.2.1.
Based on the above information, the GMO Panel considers that its previous conclusions on the
safety of the single soybean events remain valid.
3.3. Systematic literature review9
The GMO Panel assessed the applicant’s literature searches on soybean MON 87708 9
MON 89788 9 A5547-127, which included a scoping review, according to the guidelines given in EFSA
(2010).
A systematic review as referred to in Regulation (EU) No 503/2013 has not been provided in
support to the risk assessment of application EFSA-GMO-NL-2016-135. Based on the outcome of the
scoping review, the GMO Panel agrees that there is limited value in undertaking a systematic review
for soybean MON 87708 9 MON 89788 9 A5547-127 at present.
Although the overall quality of the performed literature searches is acceptable, the GMO
Panel considers that future searches on soybean MON 87708 9 MON 89788 9 A5547-127 should be
improved. The GMO Panel therefore recommends the applicant to:
• ensure that enough search term variation is used (covering possible synonyms, related terms,
acronyms, spelling variants, old and new terminology, brand and generic names, lay and
scientific terminology, common typos, translation issues);
• ensure that enough truncation is used and used consistently;
• where subject headings are available use both free-text terms and controlled vocabulary in the
searches;
• adapt the search to the size of the identified publications (and thus not combine search sets
when one of the search sets already yields only a small number of publications);
• assess the relevance and risk assessment implications of publications retrieved via searches
beyond electronic bibliographic databases.
The literature searches did not identify any relevant publications on soybean MON 87708 9
MON 89788 9 A5547-127.
3.4. Molecular characterisation
In line with the requirements laid down by Regulation (EU) No 503/2013, the possible impact of
the combination of the events on their integrity, the expression levels of the newly expressed proteins
or the biological functions conferred by the individual inserts are considered below.
3.4.1. Genetic elements and their biological function10
Soybean events MON 87708, MON 89788 and A5547-127 were combined by conventional crossing
to produce the soybean MON 87708 9 MON 89788 9 A5547-127. The structure of the inserts
7 Additional information: 31/5/2018.
8 Part II Scientific information, Section 1.2.2.2.
9 Dossier: Part II – Section 7; additional information: 31/5/2018.
10 Part II Scientific information, Section 1.2.2.2 and additional information: 25/01/2017, 31/5/2018.
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introduced into the three-event stack soybean is described in detail in the respective EFSA scientific
opinions (Table 1) and no new genetic modifications were involved. Genetic elements in the expression
cassettes of the single events are summarised in Table 2.
Intended effects of the inserts in soybean MON 87708 9 MON 89788 9 A5547-127 are
summarised in Table 3.
Based on the known biological function of the newly expressed proteins (Table 3), no foreseen
interactions at the biological level are expected.
3.4.2. Integrity of the events in the three-event stack soybean11
The genetic stability of the inserted DNA over multiple generations in the single soybean events MON
87708, MON 89788 and A5547-127 was demonstrated previously (see Table 1). Integrity of these
genetically independent events in soybean MON 87708 9 MON 89788 9 A5547-127 was demonstrated
by polymerase chain reaction (PCR) and sequence analysis, which show that the sequences of the events
(inserts and their flanking regions) in the three-event stack soybean are identical to the sequences
originally reported for the three single events.
Table 2: Genetic elements in the expression cassettes of the events stacked in soybean MON 87708
9 MON 89788 9 A5547-127
Event Promoter 5’ UTR Transit peptide Coding region Terminator
MON 87708 Full-length transcript
promoter from Peanut
chlorotic streak virus
50 UTR from
Tobacco etch
virus
RbcS
(Pisum sativum)
dmo
(Stenotrophomonas
maltophilia)
30 UTR of RbcS2
(Pisum sativum)
MON 89788 35S promoter from
Figwort mosaic virus
and promoter from the
Tsf1 gene of
Arabidopsis thaliana
50 UTR and
intron from
Tsf1 gene of
Arabidopsis
thaliana
ShkG
(Arabidopsis
thaliana)
CP4 epsps
(Agrobacterium
tumefaciens
strain CP4)
30 UTR of RbcS2
(Pisum sativum)
A5547-127 35S promoter from
Cauliflower mosaic
virus (CaMV)
– – pat
(Streptomyces
viridochromogenes)
t35S
(CaMV)
UTR: untranslated region.
–: when no element was specifically introduced to optimise expression.
Table 3: Characteristics and intended effects of the events stacked in soybean MON 87708 9 MON
89788 x A5547-127
Event Protein
Donor organism and biological
function
Intended effects in GM plant
MON 87708 DMO Based on a gene from S. maltophilia strain DI-6.
Dicamba mono-oxygenase (DMO) is an enzyme
that catalyses the demethylation of dicamba to
the non-herbicidal compound 3,6-dichlorosalicylic
acid and formaldehyde (Herman et al., 2005)
Event MON 87708 expresses DMO
protein which degrades the
herbicide dicamba and thus confers
tolerance to this herbicide
MON 89788 CP4 EPSPS Based on a gene from Agrobacterium strain CP4
(Barry et al., 2001). 5-enolpyruvyl-shikimate-3-
phosphate synthase (EPSPS) is an enzyme
involved in the shikimic acid pathway for
aromatic amino acid biosynthesis in plants and
microorganisms (Herrmann, 1995)
Event MON 89788 expresses the
bacterial CP4 EPSPS protein which
confers tolerance to glyphosate-
containing herbicides as it has lower
affinity towards glyphosate than the
plant endogenous enzyme
A5547-127 PAT Based on a gene from S. viridochromogenes,
T€u494 phosphinothricin-acetyl-transferase (PAT)
enzyme acetylates L-glufosinate-ammonium
(Thompson et al., 1987; Wohlleben et al., 1988;
Eckes et al., 1989)
Event A5547-127 expresses the PAT
protein, which confers tolerance to
glufosinate-ammonium-containing
herbicides (Droge-Laser et al.,
1994)
11 Part II Scientific information, Section 1.2.2.2 and additional information: 31/5/2018.
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3.4.3. Information on the expression of the inserts12
DMO, CP4 EPSPS and PAT protein levels were analysed by enzyme-linked immunosorbent assay
(ELISA) in material harvested from a field trial at five locations in the USA in 2015. Samples analysed
included leaf (V3–V4 and R6), seed (R8), root (R6) and forage (R6) treated with the intended
herbicides. In order to assess the changes in protein expression levels which may result from potential
interactions between the events, protein levels were determined for the three-event stack soybean and
the corresponding single events in different parts of the plant.
The levels of all the newly expressed proteins in the three-event stack soybean were comparable to
those of the single events (Appendix A). Therefore, there is no indication of an interaction that may
affect the levels of the newly expressed proteins in this stack.
3.4.4. Conclusion of the molecular characterisation
The molecular data establish that the events stacked in soybean MON 87708 9 MON
89788 9 A5547-127 have retained their integrity. Protein expression analyses show that the levels of
the newly expressed proteins are comparable in the three-event stack and in the single events.
Therefore, there is no indication of interaction that may affect the integrity of the events or the levels
of the newly expressed proteins in this stack.
Based on the known biological function of the newly expressed proteins, no foreseen interactions at
the biological level are expected.
3.5. Comparative analysis13
3.5.1. Overview of studies conducted for the comparative analysis
Application EFSA-GMO-NL-2016-135 presents data on agronomic and phenotypic characteristics, as
well as on forage and seed composition of the three-event stack soybean (Table 4).
3.5.2. Experimental field trial design and statistical analysis
At each field trial site, the following materials were grown: the three-event stack soybean, the
comparator A3555 and four of the sixteen commercial non-GM soybean reference varieties (hereafter
‘non-GM reference varieties’). All materials were treated with conventional herbicide management
regimes; in addition the field trials included the three-event stack soybean exposed to the intended
dicamba, glyphosate and glufosinate-ammonium containing herbicides on top of the conventional
herbicides.
The agronomic/phenotypic and compositional data were analysed as specified by the GMO
Panel (2010b, 2011a). This includes, for each of the two treatments of the three-event stack soybean,
the application of a difference test (between the GM soybean and the comparator) and an equivalence
test (between the GM soybean and the set of non-GM reference varieties).14 The results of the
Table 4: Overview of the comparative analysis studies to characterise the three-event stack
soybean provided in application EFSA-GMO-NL-2016-135
Study focus Study details Comparator
Non-GM reference
varieties
Agronomic and phenotypic analysis Field study, USA, 2015,
eight sites(a)
A3555 16(b)
Compositional analysis
GM: genetically Modified.
(a): The field trials were located in Boone, IA; Warren, IL; Bureau, IL; Pawnee, KS; Perquimans, NC; York, NE; Miami, OH and
Lehigh, PA.
(b): Non-GM reference varieties used in the 2015 field trials, with their corresponding maturity group indicated in brackets were
Great Lakes GL3029 (3.0); ILLINI 3477N (3.4); ILLINI 3880B (3.8); Becks 319N (3.1); A3525 (3.5); Stine 3822-2 (3.8);
A3253 (3.2): LG C3554 (3.5); Stine 3900-2 (3.9); ILLINI 6336N (3.2); Becks 389N (3.8); WILLIAMS 82 (3.9); Becks 331N
(3.3); HiSoy HS 38C60 (3.8); Stine 33E22 (3.3) and Great Lakes GL3809 (3.8).
12 Dossier: Part II – Section 1.2.2.3 and additional information: 16/6/2017 and 13/11/2018.
13 Dossier: Part II – Section 1.3; additional information: 21/4/2017 and 28/8/2017.
14 The purpose of the test of equivalence is to evaluate the estimated mean values for the GM crop taking into account natural
variability as defined by a set of non-GM references varieties with a history of safe use for consumption as food or feed.
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equivalence test are categorised into four possible outcomes (I–IV, ranging from equivalence to non-
equivalence).15
3.5.3. Suitability of selected test materials
3.5.3.1. Selection of the GM soybean line and comparator
To obtain the three-event stack GM soybean, events MON 87708 and MON 89788 were combined
by conventional crossing in soybean variety A3525. Soybean MON 87708 9 MON 89788 was then
crossed with soybean variety Benning harbouring event A5547-127 before being backcrossed and
stabilised in soybean variety A3555.
The comparator used in the field trials is the non GM soybean variety A3555, which has a genetic
background similar to that of soybean MON 87708 9 MON 89788 9 A5547-127 (as documented by
the pedigree and by the additional information), and is therefore considered the conventional
counterpart.
Both the three-event stack soybean and its conventional counterpart belong to maturity group 3.5,
which is considered appropriate for growing in environments across North America, where the
comparative field trials were conducted.
3.5.3.2. Selection of non-GM reference varieties
The 16 non-GM reference varieties with maturity groups ranging from 3.0 to 3.9 were selected by
the applicant and at each field trial site four of them were tested (see Table 4). On the basis of the
information provided on relative maturity classes, the GMO Panel considers the selected non-GM
reference varieties appropriate for the comparative assessment.
3.5.3.3. Seed production and quality
Seeds of the three-event stack soybean and the conventional counterpart were produced,
harvested and stored under similar conditions, before being sown in the field trials. The seed lots were
verified for their purity via event specific quantitative PCR analysis. The mean germination rates of the
three-event stack soybean and its conventional counterpart were 96% and 98% respectively. The GMO
Panel considers that the starting seed used as test material in the agronomic, phenotypic and
compositional studies was of acceptable quality.
3.5.3.4. Conclusion on suitability
The GMO Panel is of the opinion that the three-event stack soybean, its conventional counterpart
and the non-GM reference varieties were properly selected and of adequate quality. Therefore, the test
materials are considered suitable for the comparative analysis.
3.5.4. Representativeness of the receiving environments
3.5.4.1. Selection of field trial sites
The selected field trial sites were located in commercial soybean-growing regions of North America. The
soil characteristics of the selected fields were diverse,16 corresponding to optimal, near-optimal and
suboptimal conditions for soybean cultivation (Sys et al., 1993). The GMO Panel considers that the selected
sites reflect commercial soybean-growing regions in which the test materials are likely to be grown.
3.5.4.2. Meteorological conditions
Maximum and minimum mean temperatures and sum of precipitations were provided on a monthly
basis. No exceptional weather conditions were reported at any of the selected field trial sites. The
GMO Panel considers that the meteorological dataset falls within the range of climatic conditions
normally occurring at these sites.
15 In detail, the four outcomes are: category I (indicating full equivalence to the non-GM reference varieties); category II
(equivalence is more likely than non-equivalence); category III (non-equivalence is more likely than equivalence); and
category IV (indicating non-equivalence).
16 Soil types of the field trials were silty clay loam, loam and silt loam; soil organic matter ranged from 1.9% to 5.3% except for
site in Perquimans, NC (41.4%).
Assessment of GM soybean MON 87708 3 MON 89788 3 A5547-127
www.efsa.europa.eu/efsajournal 12 EFSA Journal 2019;17(7):5733
3.5.4.3. Management practices
The field trials included plots containing the three-event stack soybean, plots with the conventional
counterpart and plots with non-GM reference varieties, all managed according to local agricultural
practices. In addition, the field trials included plots containing the three-event stack soybean managed
following the same agricultural practices, plus exposed to the intended herbicides. A mix of the
intended dicamba and glyphosate-containing herbicides was applied at Biologische Bundesanstalt,
Bundessortenamt and Chemical Industry (BBCH) 13–15 growth stage.17 In addition, a glufosinate-
ammonium-containing herbicide was applied at BBCH 15–16 growth stage18 at least 7 days after the
dicamba and glyphosate application. The GMO Panel considers that the management practices
including sowing, harvesting and application of plant protection products were appropriate.
3.5.4.4. Conclusion on representativeness
The GMO Panel concludes that the geographical locations, soil characteristics, meteorological
conditions and management practices of the field trials are typical for receiving environments where
the test materials could be grown.
3.5.5. Agronomic and phenotypic analysis
Nine agronomic and phenotypic endpoints19 plus abiotic stressors, disease incidence and arthropod
damage were collected from the 8 sites (see Table 4). The endpoint pod shattering was not subjected
to a formal statistical analysis because more than 90% of the values were 0.
The statistical analysis (Section 3.5.2) was applied to eight endpoints, with the following results:
• For soybean MON 87708 9 MON 89788 9 A5547-127 treated with conventional herbicides,
the test of difference identified statistically significant differences from the conventional
counterpart for days to 50% flowering and seed moisture. The values of both endpoints fell
under equivalence category I.
• For soybean MON 87708 9 MON 89788 9 A5547-127 treated with the intended herbicide, the
test of difference identified statistically significant differences from the conventional
counterpart for early stand count, days to 50% flowering, plant height, seed moisture and
seed weight. The values of all the endpoints fell under equivalence category I.
3.5.6. Compositional analysis
Soybean MON 87708 9 MON 89788 9 A5547-127 seeds and forage harvested from 8 sites
(Table 4) were analysed for 74 constituents (seven in forage and 67 in seeds), including those
recommended by OECD (2012). Among the constituents analysed, 14 fatty acids (FA) in seeds were
excluded from the statistical analysis since more than 50% of the observations were below the limit of
quantification.20
The statistical analysis was applied to a total of 60 constituents (53 in seeds21 and 7 in forage22); a
summary of the outcome of the test of difference and the test of equivalence is presented in Table 5:
17 BBCH scale describes phenological stages (Meier, 2001) and BBCH 13-15 corresponds to approximately V2–V4 stages of
soybean development (Fehr and Caviness, 1977).
18 BBCH 15–16 corresponds to approximately V4–V5 stages of soybean development.
19 Early stand count, days to 50% flowering, final stand count, plant height, plant lodging, pod shattering, seed moisture, seed
weight, yield.
20 Caprylic acid (8:0), capric acid (10:0), lauric acid (12:0), myristic acid (14:0), myristoleic acid (14:1), pentadecanoic acid
(15:0), pentadecenoic acid (15:1), palmitoleic acid (16:1), heptadecanoic acid (17:0), heptadecenoic acid (17:1), c-linolenic
acid (18:3), eicosadienoic acid (20:2), eicosatrienoic acid (20:3) and arachidonic acid (20:4).
21 Seed constituents included proximates and fibre content (ash, carbohydrates, moisture, protein, total fat, acid detergent fibre
(ADF) and neutral detergent fibre (NDF)), minerals (calcium and phosphorus), amino acids (alanine, arginine, aspartic acid,
cystine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine,
tryptophan, tyrosine and valine), fatty acids (palmitic acid (16:0), stearic acid (18:0), oleic acid (18:1), linoleic acid (18:2),
linolenic acid (18:3), arachidic acid (20:0), eicosenoic acid (20:1) and behenic acid (22:0)), vitamins (vitamin E (a-tocopherol)
and vitamin K1 (phylloquinone)), isoflavones (daidzein, genistein, glycitein), other compounds (phytic acid, raffinose, soybean
lectin, stachyose, trypsin inhibitor, gly m 5 (b-conglycinin), gly m 6 (glycinin), gly m Bd 28k, gly m Bd 30k, gly m 1, gly m 3,
gly m 4 and gly m 8).
22 Forage constituents included moisture, protein, total fat, ash, carbohydrates, acid detergent fibre (ADF) and neutral detergent
fibre (NDF).
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• For soybean MON 87708 9 MON 89788 9 A5547-127 treated with the intended herbicides, all
the 31 seed endpoints for which significant differences were found between the GM soybean
and the conventional counterpart fell under equivalence category I or II, except for ADF, total
fat and behenic acid, the first two falling under equivalence category III and the behenic acid
under equivalence category IV. No statistically significant differences were found for any of the
seven forage constituents, and all fell under equivalence category I or II.
• For soybean MON 87708 9 MON 89788 9 A5547-127 treated with conventional herbicides, all
the 25 seed endpoints for which significant differences were found between the GM soybean
and the conventional counterpart fell under equivalence category I or II, except for behenic
acid that fell under equivalence category IV. No statistically significant differences were found
for any of the seven forage constituents, and all fell under equivalence category I or II.
The GMO Panel assessed all significant differences between soybean MON 87708 9 MON
89788 9 A5547-127 and its conventional counterpart, taking into account the potential impact on
plant metabolism and the natural variability observed for the set of non-GM reference varieties. Mean
estimates for the endpoints showing significant differences between soybean MON 87708 9 MON
89788 9 A5547-127 and its conventional counterpart and falling under category III/IV are given in
Table 6.
Table 5: Outcome of the comparative compositional analysis in seeds and forage for soybean MON
87708 9 MON 89788 9 A5547-127. The table shows the number of endpoints in each
category
Test of difference(a)
Treated(c) Not-treated(c)
Not
different
Significantly
different
Not
different
Significantly
different
Test of
equivalence(b)
Category I/II 28 28(d) 34 24(d)
Category III/IV – 3(e) – 1(e)
Not categorised 1(f) – 1(f) –
Total endpoints 60 60
(a): Comparison between soybean MON 87708 9 MON 89788 9 A5547-127 and its conventional counterpart.
(b): Four different outcomes: category I (indicating full equivalence to the non-GM reference varieties); category II (equivalence
is more likely than non-equivalence); category III (non-equivalence is more likely than equivalence); and category IV
(indicating non-equivalence). Not categorised means that the test of equivalence was not applied because of the lack of
variation among the non-GM reference varieties.
(c): Treated/not-treated with intended herbicides dicamba, glufosinate-ammonium and glyphosate.
(d): Endpoints with significant differences between soybean MON 87708 9 MON 89788 9 A5547-127 and its conventional
counterpart falling in equivalence category I-II (treated and not-treated).
For seeds, both treated and not-treated: arginine, aspartic acid, glutamic acid, glycine, histidine, leucine, lysine, proline,
serine, threonine, valine, stearic acid (18:0), oleic acid (18:1), linoleic acid (18:2), linolenic acid (18:3), daidzein, genistein,
protein, carbohydrates, vitamin E (a-tocopherol), vitamin K1 (phylloquinone). Only treated: phenylalanine, tyrosine, phytic
acid, stachyose, moisture, neutral detergent fibre and gly m 3. Not-treated: trypsin inhibitor, palmitic acid (16:0) and ash.
(e): Endpoints with significant differences between the soybean MON 87708 9 MON 89788 9 A5547-127 and its conventional
counterpart and falling in equivalence category III-IV. Estimated means are reported for these endpoints in Table 7.
(f): Endpoints not categorised for equivalence and without significant differences between the MON 87708 9 MON
89788 9 A5547-127 and its conventional counterpart: glycinin.
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3.5.7. Conclusions on the comparative analysis
Taking into account the natural variability observed for the set of non-GM reference varieties, the
GMO Panel concludes that:
1) None of the differences identified in the agronomic and phenotypic characteristics tested
between the three-event stack soybean and its conventional counterpart needs further
assessment regarding their potential environmental impact.
2) None of the differences identified in forage and seed composition between the three-event
stack soybean and its conventional counterpart needs further assessment regarding food
and feed safety, except for the levels of ADF (treated GM), total fat (treated GM) and
behenic acid (treated and not-treated GM) in seeds, which are further assessed in
Sections 3.6.3 and 3.6.6.
3.6. Food and feed safety assessment
3.6.1. Effects of processing
Soybean MON 87708 9 MON 89788 9 A5547-127 will undergo existing production processes used
for conventional soybean. Considering the changes observed in the compositional comparative analysis
(Section 3.5.6), the processing of the three-event stack soybean into food and feed products is not
expected to result in products being different from those of conventional non-GM soybean varieties.
3.6.2. Influence of Temperature and pH on newly expressed proteins
Effects of temperature and pH on newly expressed proteins CP4 EPSPS, DMO and PAT have been
previously evaluated by the GMO Panel (Table 1). No new information has been provided in the
context of this application.
3.6.3. Toxicology
3.6.3.1. Testing of newly expressed proteins23
Three proteins (CP4 EPSPS, DMO and PAT) are newly expressed in the three-event stack soybean
(Section 3.4.1). The GMO Panel has previously assessed these proteins in the context of the single
soybean events (Table 1), and no safety concerns were identified for humans and animals. The GMO
Panel is not aware of any new information that would change these conclusions.
Table 6: Quantitative results (estimated means and equivalence limits) for endpoints with
significant differences between soybean MON 87708 9 MON 89788 9 A5547-127 and its
conventional counterpart and falling under category III and category IV in the test of
equivalence (see Table 5)
Endpoint
Soybean MON
87708 3 MON
89788 3 A5547-
127(a)
Conventional
counterpart
Non-GM reference
varieties
Not-treated Treated Mean
Equivalence
limits
Seeds Acid detergent fibre (% dw) 13.90 15.63* 14.12 14.33 (13.07–15.59)
Total fat (% dw) 18.79 18.26* 18.73 20.09 (18.28–21.91)
Behenic acid (22:0)
(%FA)
0.27* 0.27* 0.30 0.33 (0.29–0.36)
GM: genetically modified.
(a): For the soybean MON 87708 9 MON 89788 9 A5547-127, significantly different values are marked with an asterisk, while
the outcomes of the test of equivalence are differentiated by greyscale backgrounds: white (equivalence category I or II),
light grey (equivalence category III) and dark grey (equivalence category IV). dw: dry weight; FA: fatty acids. Treated:
treated with herbicides dicamba, glufosinate-ammonium and glyphosate; not-treated: treated only with conventional
herbicides (see Section 3.5.4.3).
23 Dossier: Part II – Section 1.4.1.
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The potential for a functional interaction between the proteins newly expressed in soybean MON
87708 9 MON 89788 9 A5547-127 has been assessed with regard to human and animal health. The
CP4 EPSPS, DMO and PAT proteins are enzymes catalysing distinct biochemical reactions and acting on
unrelated substrates with high substrate specificity. On the basis of the known biological functions of
the individual newly expressed proteins (Table 3), there is currently no expectation for possible
interactions relevant to the food and feed safety of the three-event stack soybean.
In vitro protein degradation studies on CP4 EPSPS, DMO and PAT proteins have been previously
evaluated by the GMO Panel and no indications of safety concerns were identified (Table 1). In the
context of this application, no new studies addressing in vitro protein degradation of these newly
expressed proteins were provided by the applicant.
The GMO Panel concludes that there are no safety concerns for human and animal health related
to the proteins CP4 EPSPS, DMO and PAT newly expressed in the three-event stack soybean.
3.6.3.2. Testing of new constituents other than proteins
No new constituents other than newly expressed proteins have been identified in the three-event
stack soybean. Therefore, no further food and feed safety assessment of components other than the
newly expressed proteins is required.
3.6.3.3. Information on altered levels of food and feed constituents
Acid detergent fibre, total fat and behenic acid were significantly different in the three-event stack
soybean when compared with its conventional counterpart and showed a lack of equivalence with the
non-GM reference varieties (Section 3.5.6). Taking into account the biological characteristics and
functions of these compounds, the observed differences are considered of no toxicological concern.
Further information on the safety of these soybean constituents is provided in Section 3.6.6.
3.6.3.4. Testing of the whole genetically modified food and feed
Based on the outcome of the molecular characterisation assessment, comparative analysis and
toxicological assessment, no indication of findings relevant to food/feed safety related to the stability
and expression of the inserts or to interaction between the transformation events, and no
modifications of toxicological concern in the composition of the three-stack soybean have been
identified (see Sections 3.4.4, 3.5.6 and 3.6.3). Therefore, animal studies on food/feed derived from
the three-event stack soybean are not necessary (EFSA GMO Panel, 2011a).
In accordance to Regulation (EU) No 503/2013, the applicant provided a 90-day oral repeated-dose
toxicity study in rats on whole food and feed from each of the single soybean event MON 87708, MON
89788 and A5547-127. The three studies had already been provided in the context of the single-event
applications and assessed by the GMO Panel; no adverse effects related to the administration of the
respective GM diets had been identified (Table 1). In the context of the assessment of this three-event
stack soybean and in order to fulfil the requirements of Regulation (EU) No 503/2013 for 90-day
studies, upon EFSA’s request the applicant provided additional histopathological analysis and missing
information on test material and diets for the 90-day study on MON 87708; and new studies on MON
89788 and A5547-127, since the previously provided were conducted at low dose.
These studies are adapted from OECD TG 408 (1998) and comply with the principles of Good
Laboratory Practice (GLP), except for the lack of analytical determination of concentration,
homogeneity and stability of the test item in the formulated diets. It is recognised that it may not
always be technically possible to generate information on homogeneity and concentration for a test
item administrated or formulated, and the lack of such data and its impact on the validity of a study
should be justified (OECD, 2018). The GMO Panel acknowledges that there are no practical methods
available to analytically determine these for complex test items such as soybean meal in formulated
diets and considers adequate the application of proper diet preparation procedures and regular
evaluations of the mixing methods. Based on the additional information received from the applicant,
the GMO Panel considers that the diet preparation procedures in place in the facilities where the diets
for the three studies were prepared guaranteed their homogeneity and the proper concentration of the
respective test or control items. As regards the stability of the test item (soybean meal) in the diets,
the applicant considers that in accordance to product expiration standards declared by the diet
manufacturer the constituents of the diets used in these studies are stable for the duration of the
treatment. The GMO Panel considers this justification acceptable. In addition, the GMO Panel notes
that even though the diets were prepared and analysed in non-GLP facilities, standardised procedures
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and quality measures were followed. Therefore, the GMO Panel considers that this is not a major
deviation impacting these studies.
As regards the 90-day study on MON 87708, the additional histopathology analysis24 revealed
minimal bone marrow (sternum) hypocellularity in 2/12 females given the 30% test diet. This finding
was not associated with changes in related endpoints (e.g. haematology) and therefore, not
considered as being adverse. Other sporadic histopathological findings observed in this additional
histopathology dataset are considered compatible with the spontaneous background pathology of rats
of this strain and age. Therefore, the GMO Panel considers that the study is in line with Regulation
(EU) 503/2013 and confirms its previous conclusions that no adverse effects were observed in rats
given diets formulated with 15% or 30% toasted and defatted meal from soybean MON 87708.
In the new 90-day study on MON 89788,25 96 Crl:CD(SD) rats (48 per sex) were randomly
allocated to three treatment groups (control, GM-low-dose and GM-high-dose group, n = 16/sex per
group) using a stratified complete block design.26 The groups were fed diets containing 30% or
15% (w/w) defatted toasted meal from MON 89788 soybean sprayed with glyphosate-containing
herbicide (test diets) or 30% defatted toasted meal from the conventional counterpart (A5547, control
diet).27 Prior to their processing into defatted toasted meal, the control and MON 89788 seeds were
stored at 4°C up to 27 months. The applicant declares that soybean seeds under these storage
conditions and with a similar moisture content (12–13%) are described to be stable for up to
36 months, therefore the GMO Panel accepts the use of soybean seeds from MON 89788 and A5547
as starting materials for the study. The applicant declares that the presence of the MON 89788 event
was confirmed in seeds before processing to meal. Balanced diets were prepared according to the
specifications for PMI Certified Rodent LabDiet#5002. Test and control materials, as well as test and
control diets were analysed for proximates, amino acids, minerals, mycotoxins and pesticides
(including glyphosate). In-life procedures and observations and terminal procedures were conducted in
accordance to OECD TG 408 (1998). Mean, median, standard deviation, min and max were reported
for all continuous endpoints for each group and sex and per period or time as appropriate. The
statistical analysis was performed using mixed models with treatment, sex and their interaction as
fixed effects.28 For locomotor activity data, a dedicated model was set up.29 Only when the interaction
of the treatment per sex was significant, the comparison of the GM groups (30% and 15%) versus the
control group was conducted separately for the two genders. Data were analysed by cage when the
cage random effect was significantly different from zero, by animal otherwise. No mortality was
observed during the study.
No ophthalmoscopic findings were seen. Increased incidence of red staining around the nose was
observed in females given 30% test diet. This finding is considered not adverse since it was observed
in a limited number of animals on a small number of occasions (22/1,232 observations, with 15 of the
22 in just 2 animals), it was not associated with changes at functional observation batteries or at
macroscopic examination. No statistically significant differences were noted in mean body weight
between test diet-given animals and controls. Statistically significant higher mean feed consumption
(as g/cage per day and g/kg cage per day) was observed in females given 30% test diet (~20%) in
study week interval 2–3 as compared to concurrent controls. The GMO Panel considers this isolated
finding not to be treatment related. Statistically significant differences in palpebral closure (home cage
observation), ease of removal and posture (handling) were noted in animals given 15% and 30% test
diet as compared to controls. The GMO Panel considers that these findings are not adverse, being a
limited segment of the test battery, showing no progression with increased dose and representing
relatively small changes. Statistically significantly higher urination was noted at open field observation
in rats fed the 15% test diet as compared to controls. This finding is considered incidental not showing
dose relationship. No statistically significant differences in motor activity were observed between
animals given 30% or 15% test diet as compared to concurrent controls. Statistically significant
24 Aorta, bone (sternum) with bone marrow, cecum, cervix (females only), eyes with optic nerves, lung (including bronchi),
mandibular lymph node, Peyer’s Patches, skin with mammary gland (females only), skin from males (similar area), oesophagus,
pituitary, prostate (males only), mandibular salivary gland, seminal vesicles (males only), skeletal muscle, trachea, urinary
bladder, uterus (females only), and vagina (females only) from all animals given the control and 30% test diet.
25 Additional information 4/7/2018, Study MSL0029552.
26 For each sex, animals were stratified by body weight and randomly assigned by group of six to eight blocks. Within each
block, the animals were randomly assigned to the three treatment groups and housed in pairs.
27 Additional information 14/8/018.
28 The random effects included only the block for food consumption, while for the other outcomes the interaction block per
treatment was also considered to test for the cage effect.
29 Time effect and its interaction with the other fixed and random effects as additional factors was considered.
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decreased white blood cell (WBC) parameters were noted in rats given the 30% test diet when
compared to concurrent controls. These consisted in decreased WBC count (10% in females and 19%
in males), neutrophils (8% in females ad 23% in males), lymphocytes (11% in females and 18% in
males), basophils and large unstained cells (LUC). The same trend was noted in groups given the 15%
test diet when compared to controls, even though no statistical significance was achieved. The actual
mean values of these parameters from rats given the test diets fall within the historical control data
(HCD) range.30 The only exception is the mean WBC count in males administered the 30% test diet,
just minimally below the lower limit of the range of mean values from HCD; however, individual data
are within the range of historical controls. These finding are not associated with histopathological
changes in the bone marrow or in other lymphoid organs. The GMO Panel considers these findings not
adverse, being the values within the natural variability of rats of this strain, age and in these
experimental conditions. Coagulation parameters did not show statistically significant differences
between groups given the test diets and controls. At clinical chemistry, statistically significant
differences are observed for albumin/globulin ratio, glucose (males only) and sodium (females only)
when comparing the 30% test diet and the controls; for potassium, triglycerides and eosinophil count
when comparing the 15% test diet and the control. These minimal differences are considered not to
be adverse. Statistically significant lower kidney weight (absolute) was noted in animals fed the 30%
and 15% test diets compared to the control (around 5% and 7%, respectively). A significant lower
weight was also observed in males fed the 30% test diet as for the epididymides (around 6%). These
minimal changes are considered not adverse because they are not reflected in changes in the relative-
to-body organ weight and not associated with histopathological findings. At necropsy, no gross
pathological findings related to the administration of the test diets were seen. At histopathological
examination, follicular cysts and/or decreased corpora lutea were noted in the ovaries of one animal
given the control diet and in a few females given the 15% (2/16) and 30% (3/16) test diet. These rats
also showed thickened epithelium with increased keratin in the vagina. Following an additional peer
review of the data, the test facility concluded that these morphological features, i.e. ovarian follicular
cysts (non-ovulatory follicles) with subsequent decreased corpora lutea and keratinisation of the
vaginal epithelium represent a common finding in Sprague–Dawley rats of the age of those used in the
study and is often described as the persistent oestrus phase of reproductive senescence. The GMO
Panel noted that the difference in incidence between control and treated groups is not statistically
significant.31 In addition, decreased incidence of proestrus was noted in females given 15% (2/16) and
30% (2/16) test diet as compared to controls (9/16). The historical control data over several periods
confirm that the finding of proestrus consistently has a very high variability (from 10% to 100% of
animals) and should not be considered as an adverse finding in isolation. No statistically significant
differences in ovaries weight or in the uterus weight of test diet fed rats as compared to controls were
noted. Based on the available information, the GMO Panel is of the opinion that findings observed in
the female genital tract are the manifestation of a normal variability of rats of this strain and age. The
GMO Panel concludes that the 90-day study on MON 89788 is in line with the requirements of
Regulation (EU) 503/2013 and that no adverse effects were observed in rats after feeding diets
including 15% and 30% defatted toasted meal from soybean MON 897988 for 90 days.
In the new 90-day study on A5547-127 soybean, 96 Crl:CD(SD) rats (48 per sex) were randomly
allocated to three treatment groups (control, GM and reference group, n = 16/sex per group) using a
stratified complete block design.26 The groups were given diets containing approximately 30% (w/w)
defatted toasted meal from A5547-127 sprayed with glufosinate-containing herbicide (test diet), from
the conventional counterpart (A5547, control diet) and from a commercial variety (reference diet). The
reference group was introduced to provide additional data on the variability of the study endpoints;
however, no statistical comparisons were performed between the reference group and the other
groups. The seeds used to produce the test and control materials were sent to the processing facility
within 24 h from harvest, maintained at 13–19°C for 5 days and then processed into defatted toasted
meal. The identity of A5547 meal and diet was confirmed by PCR. Balanced diets were prepared
according to the specifications for PMI Certified Rodent LabDiet#5002. Test item, control and reference
materials, as well as test, control and reference diets were analysed for proximates, amino acids,
30 Historical control data range was set on data from 35 groups of control SD rats, over 470 animals for each endpoint
comparable in age, body weight, housing/environmental conditions, and given similar diets, spanning from the 5 years
preceding and conducting the study under evaluation.
31 Fisher exact test, two tailed, p < 0.05: 15% test diet p-value = 0.50; 30% test diet p-value = 0.30. For 15% & 30% test diets
combined (5/32) p-value = 0.34.
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minerals, mycotoxins and pesticides (including glufosinate and its metabolites 3-methyl-phosphinico-
propionic acid (MPP) and N-acetyl-glufosinate (NAG)). In-life procedures and observations and terminal
procedures were conducted in accordance to OECD TG 408 (1998). Mean, median, standard deviation,
min and max were reported for all continuous endpoints for each group/sex and per period or time as
appropriate.32 No A5547-127 related mortality was observed during the study. One male from the
control group was found dead on day 29 of the study and the cause of death was not determined. No
test diet related clinical signs and ophthalmoscopic findings were observed. No statistically significant
differences in mean body weight and cumulative body weight changes were observed in the GM group
compared to the control group. A statistically significant increase in mean feed consumption as
compared to controls was noted in the GM group at combined sex statistical analyses (+15.0%) and in
female (+18.8%) during study weeks 9–10. The GMO Panel notes that this increase in feed intake is
transient and not associated with differences in the body weight and cumulative body weight changes,
and thus not adverse. No statistically significant differences were noted in functional observation
batteries between the group given the test diet and the control group. A statistically significantly
higher mean ambulatory count was noted in the test group males (+19.7%) during the 0–10 min
interval and a statistically significantly lower mean ambulatory count was noted in the GM group
females (60.4%) during the 21–30 min interval when compared to the control group. The GMO
Panel considers this finding is not adverse, being a single segment of the test battery and representing
a relatively small change compared to controls. No statistically significant differences between the GM
and the control group were noted regarding haematological and coagulation analysis, or at urinalysis.
Higher aspartate transaminase was noted in females given the test diet as compared to controls. This
finding is noted to be primarily associated with one animal, and it is not considered to be test diet-
related. Lower thymus weight (absolute -15.0%, relative to final body weight 14.7%, relative to
brain weight ratio 14.6%) was noted in females given the test diet when compared to the control
group. This finding is not associated with histopathological changes in the thymus itself or in other
lymphoid organs. Moreover, no haematological changes (i.e. changes in lymphocyte count) were noted
in this group. The GMO Panel therefore considers this finding not to be adverse. No gross pathological
findings related to the administration of the test diet were observed at necropsy. The microscopic
examinations of selected organs and tissues did not identify relevant differences in the incidence and
severity of the histopathological findings related to the administration of the test diet. Sporadic
unilateral testes tubular atrophy was observed in a few rats across groups, up to severe in two rats
from the test diet fed group. This finding is not statistically significant. The GMO Panel considers this
finding a background condition, not related to the treatment with the test diet.
The GMO Panel notes that the applicant only tested one dose level. However, the dose tested was
the highest possible without inducing nutritional imbalance according to current knowledge and in
accordance with the limit test (OECD, 1998). This is considered not to compromise the study (EFSA,
2014).
The GMO Panel concludes that this study is in line with the requirements of Regulation (EU) 503/2013
and that no adverse effects were observed in rats after feeding diets including 30% of defatted toasted
meal from soybean A5547-127 for 90 days.
3.6.4. Allergenicity
For the allergenicity assessment, a weight-of-evidence approach was followed, taking into account
all the information obtained on the newly expressed proteins, as no single piece of information or
experimental method yields sufficient evidence to predict allergenicity (Codex Alimentarius, 2009; EFSA
GMO Panel, 2011a; Regulation (EU) No 503/2013). In addition, when known functional aspects of the
newly expressed protein or structural similarity to known adjuvants may indicate an adjuvant activity,
the possible role of these proteins as adjuvants is considered. When newly expressed proteins with a
potential adjuvant activity are expressed together, possible interactions increasing adjuvanticity and
impacting the allergenicity of the GM crop are assessed.
32 A repeated measures model was set up first for the two genders separately and then pooling them. Model by sex included the
treatment as a fixed effect, whereas block, time interval and interaction of time interval and diet were considered as random
effects. Cage average value was included as the repeated measurement. The pooled analysis combining sexes was performed
using a mixed effects model with diet, time, sex and double interaction of the single effects as fixed factors; random effects
were the block and the cage, the latter treated as repeated measurement.
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3.6.4.1. Assessment of allergenicity of newly expressed proteins33
The GMO Panel has previously evaluated the safety of the proteins DMO, CP4 EPSPS and PAT
proteins individually, and no concerns on allergenicity were identified in the context of the applications
assessed (Table 1). No new information on allergenicity of these proteins that might change the
previous conclusions of the GMO Panel in the context of the GM events assessed has become
available.34 Based on the current knowledge, and as none of the newly expressed proteins showed
allergenicity, no reasons for concerns on allergenicity regarding the simultaneous presence of these
newly expressed proteins in the three-event stack soybean are expected.
In addition, no information available on the structure or function of the newly expressed DMO, CP4
EPSPS and/or PAT proteins would suggest an adjuvant effect of these proteins in the three-event stack
soybean, resulting in or increasing an eventual immunoglobulin E (IgE) response to a bystander
protein.
3.6.4.2. Assessment of allergenicity of the GM plant products35
Soybean is considered a common allergenic food36 (OECD, 2012). Therefore, any potential change
in the endogenous allergenicity of the GM plant should be assessed (Regulation (EU) No 503/2013).
For such assessment, the applicant included in the comparative analysis specific allergens relevant for
soybean (Section 3.5.6) measured by specific ELISA methods, which have been previously considered
acceptable (EFSA GMO Panel, 2010c; Fernandez et al., 2013; Selb et al., 2017). The applicant also
referred to the Kunitz trypsin inhibitor as a potential soybean allergen, which is an anti-nutrient and as
such it is already assessed in the compositional analysis (Section 3.5.6). These allergens were selected
based on the list of potential soybean allergens described in the pertinent OECD document (OECD,
2012) and a scientific rational supporting their selection was provided by the applicant and considered
acceptable by the GMO Panel. No changes in the levels of endogenous allergens raising concern are
identified by the GMO Panel.
In the context of this application, the GMO Panel considers that there is no evidence that the
genetic modification might change the overall allergenicity of the three-event stack soybean when
compared with that of the conventional counterpart and the non-GM reference varieties tested.
3.6.5. Dietary exposure assessment to new constituents
In line with Regulation (EU) No 503/2013, the applicant provided dietary exposure estimates to
DMO, CP4 EPSPS and PAT proteins newly expressed in soybean MON 87708 9 MON 89788 9 A5547-
127. Dietary exposure was estimated based on protein expression levels reported in this application for
the three-event stack soybean treated with the intended herbicides (Appendix A), the current available
consumption data and feed practices, the foods and feeds currently available in the market and the
described processing conditions.
Table 7 describes the protein expression levels used to estimate both human and animal dietary
exposure.
33 Dossier: Part II – Section 1.5.1, 1.5.3.
34 The Panel notes that for DMO and CP4 EPSPS proteins an assessment regarding celiac disease was conducted by the
applicant. The assessment identified no perfect or relevant partial matches with known celiac disease peptide sequences. It is
pointed out that the requirements laid down in the recent EFSA guidance on allergenicity (2017) are not applicable to this
dossier, as described in Section ‘1.5 Transition period’.
35 Part II—Section 1.3.2, 1.3.3, 1.5.2 and additional information 25 August 2017.
36 Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food
information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and
of the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/
EC, Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC
and Commission Regulation (EC) No 608/2004.
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3.6.5.1. Human dietary exposure37
Dietary exposure was estimated across different European countries on different population groups:
young population (toddlers, ‘other children’), adult population (adolescents, adults, elderly and very
elderly) and special population (pregnant and lactating women).
For the purpose of estimating dietary exposure, the levels of newly expressed proteins in soybean
MON 87708 9 MON 89788 9 A5547-127 seeds were derived from replicated field trial sites (five
locations) in the 2015 US growing season. Mean values (fresh weight) are considered as the most
representative to estimate dietary exposure (see Table 7). Since no specific consumption data were
available on commodities containing soybean MON 87708 9 MON 89788 9 A5547-127, a conservative
scenario with 100% replacement of conventional soybean by the GM soybean was considered.
Consumption figures for the relevant commodities (soya bean flour, soya bread, textured soy protein,
soya drink, soya-based infant formula, soya-based follow-on formula, tofu, etc.) were retrieved from
the EFSA Comprehensive European Food Consumption Database (EFSA consumption database).38
Soybean oil was excluded from the assessment since no proteins are expected to be present in the oil.
For acute dietary exposure estimations, the applicant used the protein content in the different
soybean derived commodities to estimate the concentration of DMO, CP4 EPSPS and PAT proteins in
the consumed foods. This is considered a conservative approach as no losses of newly expressed
proteins are assumed during processing and all the protein content in the processed foods is
considered as derived from the GM soybean. Summary statistics from the EFSA consumption database
were used (accessed on June 2016).39
Acute dietary exposure in high consumers, within each dietary survey and age class, was estimated
by summing the exposure derived from the 95th percentile consumption for the dominant food
commodity40 among consumers only and those exposures derived from the mean consumption of the
remaining food categories in the total population (EFSA, 2015b). Among the young population, the
highest acute exposure was estimated in other children (3–10 years old), with 286 lg/kg body weight
(bw) per day, 97 lg/kg bw per day and 74 lg/kg bw per day for CP4 EPSPS, PAT and DMO proteins,
respectively. In adults (18–65 years old), the highest acute exposure estimates were 496 lg/kg bw per
day, 169 lg/kg bw per day and 128 lg/kg bw per day for CP4 EPSPS, PAT and DMO proteins,
respectively. Most relevant food commodities in terms of contribution to the exposure were soya drink
and meat imitates (textured soy protein).
The GMO Panel estimated chronic dietary exposure to CP4 EPSPS, PAT and DMO proteins.
Individual consumption data of the relevant food commodities were retrieved from the EFSA
Consumption Database, using dietary surveys with at least 2 days consumption and covering a total of
19 European countries.41 Different recipes and factors were considered to estimate the amount of
soybean in the consumed commodities before assigning CP4 EPSPS, PAT and DMO proteins levels to
Table 7: Mean values (n = 20, lg/g dry weight and lg/g fresh weight) for newly expressed
proteins in seeds and forage from soybean MON 87708 9 MON 89788 9 A5547-127
treated with a combination of the intended herbicides(a)
Protein
Tissue/developmental stage
Seeds/R8
(lg/g dry weight and lg/g fresh weight(b))
Forage/R6
(lg/g dry weight)
DMO 28  7/25  6 28  5
CP4 EPSPS 110  16/97  13 110  16
PAT 38  4/33  4 67  9
(a): Intended herbicides: dicamba, glyphosate and glufosinate-ammonium.
(b): Fresh weight values used to estimate human dietary exposure were calculated by multiplying the dry weight values (28,
110, 38 lg/g) by a dry weight correction factor of 0.88 to account for approximately 12% moisture content in the seeds.
37 Dossier: Part II – Section 2.4.
38 http://www.efsa.europa.eu/en/data/food-consumption-data
39 https://www.efsa.europa.eu/en/applications/gmo/tools
40 Dominant food commodity refers to the food that will lead to the highest exposure among all consumed foods.
41 Austria, Belgium, Bulgaria, Cyprus, the Czech Republic, Germany, Denmark, Spain, Finland, France, the United Kingdom,
Greece, Hungary, Ireland, Italy, Latvia, the Netherlands, Romania, and Sweden.
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the relevant commodities.42 No losses in the newly expressed proteins during processing were
considered. The 95th percentile chronic exposure was derived from the distribution of the individual
dietary exposure estimates within each dietary survey and age class. In the young population, the
highest 95th percentiles were estimated in other children, with 33.1 lg/kg bw per day, 11.3 lg/kg bw
per day and 8.5 lg/kg bw per day for CP4 EPSPS, PAT and DMO proteins, respectively. Corresponding
highest estimates were identified in the elderly and very elderly population (> 65 years) with 16.3 lg/kg
bw day, 5.6 lg/kg bw day and 4.2 lg/kg bw day for CP4 EPSPS, PAT and DMO proteins, respectively. The
main average contributors to the exposure in these dietary surveys were soya drink in the young
population, and meat imitates and soya beans in the elderly and very elderly population.
A worst-case exposure scenario to cover dietary exposure to CP4 EPSPS, PAT and DMO proteins
following the consumption of protein isolates (~90% protein) as protein supplements was investigated.
In the absence of consumption data, high consumers of protein (95th percentile) in the European
adult population (EFSA NDA Panel, 2012) were considered (up to 189 g/day). Assuming that all
consumed protein was from soybean MON 87708 9 MON 89788 9 A5547-127 protein isolates, the
estimated exposure to CP4 EPSPS, PAT and DMO in adults (body weight 70 kg) would be around
718 lg/kg bw day, 244 lg/kg bw day, and 185 lg/kg bw day, respectively.
3.6.5.2. Animal dietary exposure43
Animal dietary exposure to CP4 EPSPS, PAT and DMO proteins was estimated following the
consumption of soybean meal and soybean forage/silage since these are the two soybean products
entering the feed chain. A conservative scenario with 100% replacement of conventional soybean
products by the GM products was considered.
Mean levels of CP4 EPSPS, PAT and DMO proteins in soybean seeds and forage/silage were derived
from replicated field trial sites (five locations) in the 2015 US growing season (Table 7). To estimate
the mean newly expressed protein levels in soybean meal a factor of 1.28 fold was applied based on
the protein content of soybean meal relative to soybean seed (OECD, 2012), assuming that no losses
of newly expressed protein occur during processing.
Dietary exposure to CP4 EPSPS, PAT and DMO proteins in soybean MON 87708 9 MON 89788 9
A5547-127 following the consumption of soybean meal was provided by the applicant across different
animal species (i.e. broiler, finishing pig and lactating dairy cattle), based on estimates for animal body
weight, daily feed intake and inclusion rates (percentage) of soybean meal in animal diets (OECD,
2009). Estimated dietary exposure was as follows:
 To CP4 EPSPS protein, 3,976 lg/kg bw per day in broiler chickens, 1354 lg/kg bw per day in
dairy cattle and 1,267 lg/kg bw per day in finishing pig.
 To PAT protein, 1,373 lg/kg p bw per day in broiler chickens, 468 lg/kg bw per day in dairy
cattle and 438 lg/kg bw per day in finishing pig.
 To DMO protein, 1,012 lg/kg bw per day in broiler, 345 lg/kg bw per day in dairy cattle and
323 lg/kg bw per day in finishing pig.
The GMO Panel estimated dietary exposure to CP4 EPSPS, PAT and DMO proteins in lactating dairy
cows following the consumption of soybean forage/silage, based on estimates for animal body weight
and daily feed intake (OECD, 2009), and for inclusion rates of soybean forage/silage in animal diets
(OECD, 2012). Estimated dietary exposure in lactating dairy cows was 847 lg/kg bw per day, 516 lg/kg
bw per day and 216 lg/kg bw per day for CP4 EPSPS, PAT and DMO proteins, respectively.
3.6.6. Nutritional assessment of endogenous constituents
The intended traits of the three-event stack soybean are herbicide tolerance, with no intention to
alter nutritional parameters. However, ADF, total fat and behenic acid were significantly different from
its conventional counterpart and showed a lack of equivalence with the set of non-GM reference
varieties (Section 3.5.6). The biological relevance of these compounds, the role of soybean as
contributor to their total intake and the magnitude and direction of the observed changes were
considered during the nutritional assessment.
42 Example: 100 grams of Tofu are made with approximately 26 grams of soy beans; this would result in 25.2 µg of CP4 EPSPS
per gram of tofu as compared to 97 µg/g in the soy beans.
43 Dossier: Part II – Section 2.3.
Assessment of GM soybean MON 87708 3 MON 89788 3 A5547-127
www.efsa.europa.eu/efsajournal 22 EFSA Journal 2019;17(7):5733
3.6.6.1. Human nutrition
In the context of human nutrition, fibre is referred to as dietary fibre, which primarily includes non-
starch polysaccharides (mainly cellulose, hemicelluloses, pectins, and other hydrocolloids) and lignin
(EFSA NDA Panel, 2010). Therefore, the observed increase (~ 11%) in ADF (cellulose and lignin)
implies an increase of dietary fibre. Dietary fibre is present in certain soybean derived foods (e.g.
soybean flour), while it is almost absent in other products such as tofu and soya milk. Although
evidences link high consumption of fibre (above 25 grams per day) with health benefits (EFSA NDA
Panel, 2010), foods from soybean are, overall, not major contributors to total dietary fibre intake.
Therefore, the nutritional impact of the increase in ADF is not considered relevant for human nutrition.
The decrease in total fat (~ 3%) is not considered relevant for human nutrition, also because no
significant differences in the profile of FA beyond behenic acid were observed. Behenic acid is a
saturated FA (22:0) present in vegetable oils in very small amounts (< 1% total FA) although levels
around 3% of the total FA have been reported in peanut oil (Ozcan and Seven, 2003). Considering the
very low levels of behenic acid in soybean (< 1% total FA) and the observed decrease as compared to
the conventional counterpart, the GMO Panel concludes that the nutritional impact of foods derived
from soybean MON 87708 9 MON 89788 9 A5547-127 is similar to that of foods derived from its
conventional counterpart and non-GM reference varieties.
3.6.6.2. Animal nutrition
Animal complete diets are balanced, i.e. ADF and total fat from feed ingredients are taken into
account to meet animal nutritional requirements. Considering the very low levels of behenic acid in
soybean (< 1% total FA) and the observed decrease as compared to the conventional counterpart, the
nutritional impact in feeds is considered negligible.
3.6.6.3. Conclusion on human and animal nutrition
Based on the current knowledge on the biological role of the compounds assessed, the magnitude
and direction of the changes identified, and the relevance of soybean as contributor to the intake of
these compounds, the GMO Panel concludes that the nutritional impact of foods and feeds from the
three-event stack soybean is expected to be the same as those from its conventional counterpart and
non-GM reference varieties.
3.6.7. Conclusion of the food and feed safety assessment
The proteins DMO, CP4 EPSPS and PAT newly expressed in soybean MON 87708 9 MON
89788 9 A5547-127 do not raise safety concerns for human and animal health. Interactions between
these newly expressed proteins raising food and feed safety concerns (toxicology, allergenicity and
adjuvanticity) are not expected. There is no evidence that the genetic modification might change the
overall allergenicity of the three-event stack soybean. The nutritional impact of the three-event stack
soybean foods and feeds is expected to be the same as that of foods and feeds derived from its
conventional counterpart and non-GM reference varieties. The GMO Panel concludes that the three-
event stack soybean, as described in this application, is as safe as and nutritionally equivalent to its
conventional counterpart and the non-GM reference varieties tested.
3.7. Environmental risk assessment44
Considering the scope of application EFSA-GMO-NL-2016-135, which excludes cultivation, the
environmental risk assessment (ERA) of the three-event stack soybean mainly takes into account: (1)
the exposure of microorganisms to recombinant DNA in the gastrointestinal tract of animals fed GM
material and of microorganisms present in environments exposed to faecal material of these animals
(manure and faeces); and (2) the accidental release into the environment of viable the three-event
stack soybean seeds during transportation and/or processing (EFSA GMO Panel, 2010b).
3.7.1. Persistence and invasiveness of the GM plant
Cultivated soybean (Glycine max (L.) Merr.) is a species in the subgenus Soja of the genus Glycine.
The species originated from eastern Asia and is a highly domesticated crop, generally unable to survive
in the environment without appropriate management (Lu, 2005).
44 Dossier: Part II – Section 5; additional information: 31/5/2018.
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Occasional feral GM soybean plants may occur outside cultivation areas, but survival is limited
mainly by a combination of low competitiveness, absence of a dormancy phase and susceptibility to
plant pathogens and cold climatic conditions (OECD, 2000). Soybean can grow as volunteers and the
presence of volunteers of G. max was occasionally reported in some areas of Italy where soybean is
intensively cultivated (Celesti-Grapow et al., 2010). However, as for the same reasons mentioned
above, soybean seeds usually do not survive during the winter (Owen, 2005). Thus, the establishment
and survival of feral and volunteer soybean in the EU is currently limited and transient.
It is unlikely that the intended traits of the three-event stack soybean will provide a selective
advantage to soybean plants, except when they are exposed to glyphosate-, dicamba- and/or
glufosinate-containing herbicides. However, this fitness advantage will not allow the GM plant to
overcome other biological and abiotic factors (described above) limiting plant’s persistence and
invasiveness. Therefore, the presence of the intended traits will not affect the persistence and
invasiveness of the GM plant.
In conclusion, the GMO Panel considers it very unlikely that the three-event stack soybean will
differ from conventional soybean hybrid varieties in its ability to survive until subsequent seasons, or to
establish occasional feral plants under European environmental conditions in case of accidental release
into the environment of viable seeds of the three-event stack soybean.
3.7.2. Potential for gene transfer
A prerequisite for any gene transfer is the availability of pathways for the transfer of genetic
material, either through HGT of DNA, or through vertical gene flow via cross-pollination from feral
plants originating from spilled seeds.
3.7.2.1. Plant-to-microorganism gene transfer
The probability and potential adverse effects of HGT of the recombinant DNA have been assessed
in previous GMO Panel scientific opinions for the single events (see Table 1). This assessment included
consideration of homology-based recombination processes, as well as non-homologous end joining and
microhomology-mediated end joining. Possible fitness advantages that the bacteria in the receiving
environments would gain from acquiring recombinant DNA were considered. No concern as a result of
an unlikely, but theoretically possible, HGT of the recombinant genes to bacteria in the gut of
domesticated animals and humans fed GM material or other receiving environments was identified.
The applicant submitted an updated bioinformatic analysis for each of the single events to assess the
possibility for HGT by HR.
The updated bioinformatic analysis for event MON 87708 revealed two elements with sufficient
length and sequence identity with bacterial genes in databases: the dmo gene from S. maltophilia, and
the left border sequence from the Agrobacterium tumefaciens Ti plasmid. Considering that these
sequences do not occur in the same bacterial species, there is no indication for facilitated double HR
from MON 87708 confirming the conclusions of a previous EFSA GMO Panel Scientific Opinion (EFSA
GMO Panel, 2015b).
The updated bioinformatic analysis for event MON 89788 revealed no homology with known DNA
sequences from bacteria which would facilitate HR confirming the conclusions of a previous EFSA GMO
Panel Scientific Opinion (EFSA GMO Panel, 2015b).
The potential for HGT of event A5547-127 has been recently assessed by the GMO Panel in the
context of application EFSA-GMO-NL-2013-120 (EFSA GMO Panel, 2017). The assessment, based on
updated bioinformatic analysis, confirmed that double HR could occur between the non-functional bla
gene fragments of event A5547-127, with a chromosomally located bla gene, leading to a
chromosomally inserted pat gene. Due to its plant codon optimisation, it is expected that the newly
acquired pat gene would not provide a selective advantage to bacterial recipients. Confirming the
previous conclusion of the GMO Panel, no risk was identified for HGT of the recombinant DNA derived
from event A5547-127.
Synergistic effects of the recombinant genes, for instance due to combinations of recombinogenic
sequences, which would cause an increase in the likelihood for HGT or a selective advantage were not
identified.
Therefore, the GMO Panel concludes that the unlikely, but theoretically possible, horizontal transfer
of recombinant genes from this three-event stack soybean to bacteria does not raise any
environmental safety concern.
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3.7.2.2. Plant-to-plant gene transfer
The potential for occasional feral soybean MON 87708 9 MON 89788 9 A5547-127 plants
originating from seed import spills to transfer recombinant DNA to sexually compatible plants and the
environmental consequences of this transfer were considered.
For plant-to-plant gene transfer to occur, imported GM soybean seeds need to germinate and
develop into plants in areas containing sympatric wild relatives and/or cultivated soybean with
synchronous flowering and environmental conditions favouring cross-pollination. It must be noted that
most soybean MON 87708 9 MON 89788 9 A5547-127 seeds are processed in the countries of
production or in ports of importation.
Vertical gene transfer from soybean (G. max) is limited to the species of the subgenus Soja to
which G. max belongs to, as well as the wild relatives G. soja and G. gracilis. Although wild relatives
exist elsewhere, no wild relatives of the subgenus Soja have been reported in Europe (Dorokhov et al.,
2004; Lu, 2005). Therefore, vertical gene transfer from GM soybean is restricted to cultivated soybean
(G. max).
Soybean is an annual, almost completely self-pollinating crop with a percentage of cross-pollination
usually below 1% (OECD, 2000; Ray et al., 2003; Lu, 2005; Yoshimura et al., 2006; Abud et al., 2007),
although natural cross-pollination rates can fluctuate significantly among different soybean varieties
under particular environmental conditions, such as favourable climate for pollination and an abundance
of pollinators (Caviness, 1966; Gumisiriza and Rubaihayo, 1978; Kikuchi et al., 1993; Ahrent and
Caviness, 1994; Ray et al., 2003; Lu, 2005).
The potential of spilled soybean seeds to establish, grow and produce pollen is extremely low and
transient (see Section 3.7.1). Therefore, the likelihood/frequency of cross-pollination between
occasional feral GM soybean plants resulting from seed spillage, and weedy or cultivated soybean
plants is also considered extremely low. Even if cross-pollination would occur, the GMO Panel is of the
opinion that the likelihood of environmental effects as a consequence of the spread of genes from
occasional feral GM soybean plants in Europe will not differ from that of conventional soybean varieties
for the reasons given in Section 3.7.1.
3.7.3. Interactions of the GM plant with target organisms
Taking the scope of application EFSA-GMO-NL-2016-135 (no cultivation) and thus the absence of
target organisms into account, potential interactions of occasional feral three-event stack soybean
plants arising from seed import spills with target organisms are not considered a relevant issue.
3.7.4. Interactions of the GM plant with non-target organisms
Given that environmental exposure of non-target organisms to spilled GM seeds or occasional feral
GM soybean plants arising from spilled three-event stack soybean seeds is limited, and because
ingested proteins are degraded before entering the environment through faecal material of animals fed
GM soybean, potential interactions of the three-event stack soybean with non-target organisms are not
considered to raise any environmental safety concern.
3.7.5. Interactions with abiotic environment and biogeochemical cycles
Given that environmental exposure to spilled seeds or occasional feral three-event stack soybean
plants arising from seed import spills is limited, and because ingested proteins are degraded before
entering the environment through faecal material of animals fed GM soybean, potential interactions
with the abiotic environment and biogeochemical cycles are not considered to raise any environmental
safety concern.
3.7.6. Conclusion of the environmental risk assessment
The GMO Panel concludes that it is unlikely that the three-event stack soybean would differ from
conventional soybean varieties in its ability to persist under European environmental conditions.
Considering the scope of application EFSA-GMO-NL-2016-135, interactions of occasional feral three-
event stack soybean plants with the biotic and abiotic environment are not considered to be relevant
issues. The analysis of HGT from the three-event stack soybean to bacteria does not indicate a safety
concern. Therefore, considering the combined events and their potential interactions, the outcome of
the comparative analysis, and the routes and levels of exposure, the GMO Panel concludes that the
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three-event stack soybean would not raise safety concerns in the event of accidental release of viable
GM soybean seeds into the environment.
3.8. Post-market monitoring
3.8.1. Post-market monitoring of GM food/feed
There was no indication that food/feed products derived from the three-event stack soybean are
less safe or nutritious than those derived from the non-GM conventional counterpart. Furthermore, the
overall intake or exposure is not expected to change because of the introduction of the three-event
stack soybean into the market. Therefore, the GMO Panel considers that Post-Market Monitoring (PMM)
of food and feed from the three-event stack soybean is not necessary.
3.8.2. Post-market environmental monitoring45
The objectives of a PMEM plan, according to Annex VII of Directive 2001/18/EC, are: (1) to confirm
that any assumption regarding the occurrence and impact of potential adverse effects of the GMO, or
its use, in the ERA are correct; and (2) identify the occurrence of adverse effects of the GMO, or its
use, on human health or the environment that were not anticipated in the ERA.
Monitoring is related to risk management, and thus a final adoption of the PMEM plan falls outside
the mandate of EFSA. However, the GMO Panel gives its opinion on the scientific rationale of the PMEM
plan provided by the applicant (EFSA GMO Panel, 2011b).
As the ERA did not identify potential adverse environmental effects from the three-event stack
soybean, no case-specific monitoring is required.
The PMEM plan proposed by the applicant for the three-event stack soybean includes: (1) the
description of a monitoring approach involving operators (federations involved in import and
processing), reporting to the applicant, via a centralised system, any observed adverse effect(s) of
GMOs on human health and the environment; (2) a coordinating system established by EuropaBio for
the collection of information recorded by the various operators; and (3) the review of relevant
scientific publications retrieved from literature searches (Lecoq et al., 2007; Windels et al., 2008). The
applicant proposes to submit a PMEM report on an annual basis and a final report at the end of the
authorisation period.
The GMO Panel considers that the scope of the PMEM plan provided by the applicant is consistent
with the intended uses of the three-event stack soybean. The GMO Panel agrees with the reporting
intervals proposed by the applicant in its PMEM plan.
In the context of annual PMEM reports, the applicant should improve future literature searches
according to the GMO Panel recommendations given in Section 3.3.
3.8.3. Conclusion on post-market monitoring
No PMM of food and feed is necessary. The scope of the PMEM plan provided by the applicant and
the reporting intervals are in line with the intended uses of the three-event stack soybean.
3.9. Overall conclusions
The GMO Panel was asked to carry out a scientific assessment of soybean MON 87708 9 MON
89788 9 A5547-127 for import, processing and food and feed uses in accordance with Regulation (EC)
No 1829/2003.
No new information on the single soybean events MON 87708, MON 89788 and A5547-127 that
would lead to a modification of the original conclusions on their safety were identified.
The molecular characterisation, the comparative analysis (agronomic, phenotypic and compositional
characteristics) and the outcome of the toxicological, allergenicity and nutritional assessment indicate
that the combination of the single soybean events and of the newly expressed proteins in the three-
event stack soybean does not give rise to food/feed safety and nutritional concerns. The GMO
Panel concludes that the three-event stack soybean, as described in this application, is as safe as and
nutritionally equivalent to its conventional counterpart and the non-GM reference varieties tested.
The GMO Panel concludes that there is a very low likelihood of environmental effects resulting from
the accidental release of viable seeds from the three-event stack soybean into the environment.
45 Dossier: Part II – Section 6.
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Based on the relevant publications identified through the literature searches, the GMO Panel did not
identify any safety issues pertaining to the intended uses of soybean MON 87708 9 MON
89788 9 A5547-127. In the context of annual PMEM reports, the applicant should improve future
literature searches according to the GMO Panel recommendations.
In addition, the GMO Panel considered the additional unpublished studies listed in Appendix B. This
new information does not raise any concern for human and animal health and the environment,
regarding soybean MON 87708 9 MON 89788 9 A5547-127.
Given the absence of safety concerns for foods and feeds from the soybean MON 87708 9 MON
89788 9 A5547-127, the GMO Panel considers that PMM of these products is not necessary. The
PMEM plan and reporting intervals are in line with the intended uses of the three-event stack soybean.
In conclusion, the GMO Panel considers that soybean MON 87708 9 MON 89788 9 A5547-127, as
described in this application, is as safe as its conventional counterpart and the tested non-GM
reference varieties with respect to potential effects on human and animal health and the environment.
Documentation provided to EFSA
1) Letter from the Competent Authority of Netherlands received 03 November 2016
concerning a request for authorisation for the placing on the market of soybean MON
87708 9 MON 89788 9 A5547-127 (reference EFSA-GMO-NL-2016-135) submitted in
accordance with Regulation (EC) No 1829/2003 by Monsanto Europe S.A./N.V.
2) Application EFSA-GMO-NL-2016-135 validated by EFSA, 19 January 2017.
3) Request for supplementary information to the applicant, 25 January 2017.
4) Receipt of supplementary information from the applicant, 30 January 2017.
5) Request for supplementary information to the applicant, 23 February 2017.
6) Receipt of supplementary information from the applicant, 21 April 2017.
7) Request for supplementary information to the applicant, 11 May 2017.
8) Receipt of supplementary information from the applicant, 16 June 2017.
9) Request for supplementary information to the applicant, 26 June 2017.
10) Request for supplementary information to the applicant, 12 July 2017.
11) Receipt of supplementary information from the applicant, 17 July 2017.
12) Receipt of supplementary information from the applicant, 28 August 2017.
13) Request for supplementary information to the applicant, 15 February 2018.
14) Receipt of supplementary information from the applicant, 16 March 2018.
15) Receipt of spontaneous information from the applicant, 27 April 2018.
16) Receipt of spontaneous information from the applicant, 31 May 2018.
17) Receipt of supplementary information from the applicant, 04 July 2018.
18) Request for supplementary information to the applicant, 18 July 2018.
19) Receipt of supplementary information from the applicant, 14 August 2018.
20) Request for supplementary information to the applicant, 30 August 2018.
21) Request for supplementary information to the applicant, 13 September 2018.
22) Receipt of supplementary information from the applicant, 28 September 2018.
23) Receipt of supplementary information from the applicant, 28 September 2018.
24) Receipt of supplementary information from the applicant, 06 November 2018
25) Request for supplementary information to the applicant, 08 November 2018.
26) Receipt of supplementary information from the applicant, 13 November 2018.
27) Request for supplementary information to the applicant, 29 November 2018.
28) Receipt of supplementary information from the applicant, 12 December 2018
29) Request for supplementary information to the applicant, 21 December 2018.
30) Receipt of supplementary information from the applicant, 22 January 2019.
31) Receipt of spontaneous information from the applicant, 20 March 2019.
32) Receipt of spontaneous information from the applicant, 02 April 2019.
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Appendix A – Protein expression data
Mean, standard deviation and range of protein levels (lg/g dry weight) from soybean MON
87708 9 MON 89788 9 A5547-127 (treated with dicamba, glyphosate and glufosinate-ammonium),
MON 87708 (treated with dicamba), MON 89788 (treated with glyphosate) and A5547-127 (treated
with glufosinate-ammonium) from a field trial performed across five locations in USA in 2015 (n = 20).
Protein Event(s) Leaf (V3–V4) Leaf (R6) Forage (R6) Root (R6) Seed (R8)
DMO MON 87708 3 MON
89788 3 A5547-127
12.4(a)  4.4(b)
(5.7–20)(c)
46  18
(23–86)
28  5.3
(20–37)
4.4  2.8
(1.3–11)
28  7.3
(21–57)
MON 87708 12  4.0
(6.1–18)
48  27
(19–110)
29  5.4
(20–40)
4.6  3.1
(1.1–12)
26  4.1
(11–35)
CP4 EPSPS MON 87708 3 MON
89788 3 A5547-127
170  38
(100–240)
170  43
(74–270)
110  16
(91–150)
22  9.8
(8.1–43)
110  16
(78–140)
MON 89788 180  57
(96–350)
180  38
(130–280)
130  11
(100–150)
53  14
(35–88)
110  11
(95–140)
PAT MON 87708 3 MON
89788 3 A5547-127
82  21
(39–130)
100  37
(40–180)
67  9.4
(50–86)
19  6.8
(9.0–31)
38  4.4
(30–45)
A5547-127 66  11
(43–85)
110  20
(80–150)
54  9.7
(37–71)
23  8.2
(9.8–38)
37  5.6
(24–46)
DMO: dicamba mono-oxygenase; EPSPS: 5-enolpyruvylshikimate-3-phosphate synthase; PAT: phosphinothricin acetyltransferase.
(a): Mean.
(b): Standard deviation.
(c): Range.
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Appendix B – List of additional unpublished studies performed by or on
behalf of the applicant with regard to the evaluation of the safety of the
food and feed for humans, animal and the environment for soybean MON
87708 3 MON 89788 3 A5547-127
Study
identification
Title
MSL0027645 Phenotypic Evaluation and Environmental Interactions of Soybean MON 87708 9 MON
89788 9 A5547-127 in 2015 U.S. Field Trials
MSL0027453 Analyses of Minerals and B Vitamins of Soybean Seed from MON 87708 9 MON
89788 9 A5547-127 Grown in the United States in 2015
MSL0027882 Comparison of Gly m 4 Expression Levels from MON 87708 9 MON 89788 9 A5547-127
and Conventional Soybeans
MSL0027424 Southern Blot Analyses to Confirm the Presence of MON 87708, MON 89788 and A5547-127
in the Combined Trait Soybean Product MON 87708 9 MON 89788 9 A5547-127
Assessment of GM soybean MON 87708 3 MON 89788 3 A5547-127
www.efsa.europa.eu/efsajournal 32 EFSA Journal 2019;17(7):5733
